World News: 13:30 GMT Thursday 6th December 2018. [BriaCell Therapeutics Corp via Globe Newswire via SPi World News]
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 06, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("" or the "") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announces the presentation of initial safety data in the combination study of its lead candidate, Bria-IMT™, with pembrolizumab [KEYTRUDA; manufactured by Merck & Co., Inc. (NYSE: MRK)] and confirmation of positive proof of concept data of Bria-IMT™ for advanced breast cancer at the 2018 San Antonio Breast Cancer Symposium (SABCS). The combination study is listed in ClinicalTrials.gov as NCT03328026.
“I am very excited about our data continuing to show robust biological activity of Bria-IMT™ in advanced breast cancer,” commented Dr. Bill Williams, BriaCell’s president & CEO. “These findings also reinforce our product development strategy for Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy, by showing predictability of the anti-tumor responses in patients using a relatively simple and inexpensive HLA test.
“Based on the data of three proof of concept studies to-date, Bria-IMT™ has shown the ability to produce powerful immune responses and elicit tumor regression even in heavily pre-treated patients with very advanced disease. We are highly confident of our strategy to use Bria-IMT™ in combination with KEYTRUDA, an approved treatment for multiple cancer indications, and expect synergistic activity of this combination in patients with advanced breast cancer. We look forward to additional clinical data and expect to share details at upcoming scientific meetings.”
Initial safety data on the Bria-IMT™/KEYTRUDA combination study and additional confirmatory Phase I/IIa data from the Bria-IMT™ monotherapy study, a subset of which was the subject of , was presented this morning in detail by , DO, assistant professor of Medical Oncology at and researcher at the NCI-designated – .
BriaCell is on track to present initial efficacy data on the combination in 1Q19.
Activation of T cells, an important component of the immune system, was measured by delayed-type hypersensitivity (DTH) testing during treatment. Even though 60% of the patients could not mount a DTH response to a common yeast, Bria-IMT™ treatment elicited a DTH response in 59% of the patients and this was particularly robust in the patients with tumor regression. This indicates Bria-IMT™ elicits a robust immune response in these patient population.
Following the presentation, copies of the abstract and the poster will be posted on .
Since its inception in 1977, San Antonio Breast Cancer Symposium (SABCS) has grown to a five-day program that covers the latest research on the experimental biology, etiology, prevention, diagnosis, and treatment of breast cancer and premalignant breast disease. The Symposium is attended by a large international audience of researchers, health professionals, physicians, oncologists, and those with a special interest in breast cancer from over 90 countries.
To complement the clinical focus of the annual SABCS, Baylor College of Medicine became a joint sponsor of SABCS in 2005. Additionally, the Cancer Therapy & Research Center (CTRC) at UT Health Science Center San Antonio and American Association for Cancer Research (AACR), a prestigious scientific organization known for its basic, translational and clinical cancer research, began collaboration with SABC in 2007. The Symposium was renamed the CTRC-AACR San Antonio Breast Cancer Symposium.
For additional information on 2018 SABCS, please visit: https://www.sabcs.org.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.
BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, in a combination study with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.]. The combination study is listed in ClinicalTrials.gov as NCT03328026.
BriaCell is developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS™, which is expected to cover over 90% of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies.
For additional information on BriaCell, please visit website: .
Except for the statements of historical fact, this news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company's public filings available at .
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:Farrah DeanManager, Corporate DevelopmentEmail: Phone: 1-888-485-6340
Globe Newswire: 13:30 GMT Thursday 6th December 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.